A three-year follow-up study of psoriasis patients treated with low dosages of etretinate orally and corticosteroids topically.
Etretinate 0.5 mg/kg body weight combined with 0.1% triamcinolone acetonide and 5% salicylic acid in an O/W cream gave more than 70% improvement in 62% of 75 patients. Of this satisfactorily improved group, at least 41% were still in the same condition after 3 years on a maintenance dose of, on average, 0.3 mg/kg body weight etretinate daily and 20 g weekly of a relatively strong corticosteroid cream. The side effects were acceptable and the convenience for the patients is great as compared with other treatment.
D000284:Administration, Oral; D000287:Administration, Topical; D000505:Alopecia / Q000139:chemically induced; D001284:Atrophy / Q000139:chemically induced; D005050:Etretinate / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D011565:Psoriasis / Q000188:drug therapy*; D012867:Skin / Q000473:pathology; D014212:Tretinoin / Q000031:analogs & derivatives*
D014212:Tretinoin; D005050:Etretinate